YouTube Facebook LinkedIn Google+ Twitter Xingrss  

The Money Question: Cost-Effectiveness in Drug Discovery

April 3, 2012 | Cost-effectiveness in biotech and drug discovery can no longer be a secondary consideration, but the cost of drugs to patients is still not frequently discussed. No matter how effective a drug candidate is, the eventual costs to patients or payors must be a primary part of the drug discovery conversation. Xconomy
View Next Related Story
PacBio at AGBT | Mar 03, 2015
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 ,